Vericel (VCEL) Misses Q1 EPS by 1c, Revenues Miss; Raises FY19 Total MACI and Epicel Sales Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Vericel Reports First Quarter 2019 Financial Results and Raises Full Year 2019 Revenue Guidance
May 7, 2019 7:02 AM EDTMACI Revenue Increased 38% Over First Quarter 2018
Positive Cash Flow in First Quarter
Announced Exclusive License Agreement with MediWound for North American Rights to NexoBrid
Conference Call Today at 8:00am Eastern Time
CAMBRIDGE, Mass., May 07, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ: VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today reported financial results for the first quarter ended March 31, 2019, and recent business highlights.
First... More
